Ionis Pharmaceuticals (IONS) Accumulated Expenses (2009 - 2026)

Ionis Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $126.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 376.2% year-over-year to $126.5 million; the TTM figure through Mar 2026 stood at $126.5 million (up 376.2% YoY), while the FY2025 annual figure was $116.2 million, up 66.97% from the prior year.
• Accumulated Expenses was $126.5 million for Q1 2026 at Ionis Pharmaceuticals, up from $116.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $147.9 million in Q4 2023 to a low of $18.2 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $81.6 million across 5 years, with a median of $99.3 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses tumbled 81.7% in 2023, then surged 483.96% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $140.1 million in 2022, then gained by 5.56% to $147.9 million in 2023, then slumped by 52.93% to $69.6 million in 2024, then surged by 66.97% to $116.2 million in 2025, then advanced by 8.87% to $126.5 million in 2026.
• The last three Accumulated Expenses figures came in at $126.5 million (Q1 2026), $116.2 million (Q4 2025), and $57.0 million (Q3 2025), per Business Quant data.